This paper presents a sociological examination of the role of genetic counselors as advocates, not only for patients and their families, but also for genetic conditions themselves. In becoming activists for new disorders, genetic counselors are helping to create new categories that will shape expectations and treatment regimens for both existing patients and those who are yet to be diagnosed. By virtue of their expertise and their position at the intersection of several key professions and constituencies, genetic counselors are likely to play a central role in the way the genetic testing technologies, and especially ‘genotype-first’ diagnosis, impacts the way we understand and categorize developmental difference. I outline some of the promises and dangers that this kind of activism holds for people with developmental disabilities, and particularly the challenge presented by systemic ascertainment bias in the face of genotype-phenotype uncertainty. I argue that new testing techniques like microarray analysis that do not need to be targeted on the basis of clinical presentation throw these challenges into sharp relief, and that the genetic counseling community should consider how to marry advocacy for new genetic conditions with an emphasis on the indeterminate developmental potential of every child.
This is a preview of subscription content, access via your institution.
Aronowitz, R. A. (1999). Making sense of illness: Science, society and disease. Cambridge University Press.
Bassett, A. S., McDonald-McGinn, D. M., Devriendt, K., Digilio, M. C., Goldenberg, P., Habel, A., et al. (2011). Practical guidelines for managing patients with 22q11.2 deletion syndrome. The Journal of Pediatrics, 159(2), 332.e1–339.e1.
Beckwith, J. (1972). Science for the people. Annals of the New York Academy of Sciences, 196(4), 236–240.
Bosk, C. L. (1992). All God’s mistakes: Genetic counseling in a pediatric hospital (1st ed.). University Of Chicago Press.
Bretelle, F., Beyer, L., Pellissier, M. C., Missirian, C., Sigaudy, S., Gamerre, M., et al. (2010). Prenatal and postnatal diagnosis of 22q11.2 deletion syndrome. European Journal of Medical Genetics, 53(6), 367–370.
Brown, A., Phelan, M. C., Patil, S., Crawford, E., Rogers, R. C., & Schwartz, C. (1996). Two patients with duplication of 17p11.2: The reciprocal of the Smith-Magenis syndrome deletion? American Journal of Medical Genetics, 63(2), 373–377.
Costain, G., Chow, E. W. C., Ray, P. N., & Bassett, A. S. (2012). Caregiver and adult patient perspectives on the importance of a diagnosis of 22q11.2 deletion syndrome. Journal of Intellectual Disability Research.
Deak, K. L., Horn, S. R., & Rehder, C. W. (2011). The evolving picture of microdeletion/microduplication syndromes in the age of microarray analysis: Variable expressivity and genomic complexity. Clinics in Laboratory Medicine, 31(4), 543–564.
Driscoll, D. A., Spinner, N. B., Budarf, M. L., McDonald-McGinn, D. M., Zackai, E. H., Goldberg, R. B., et al. (1992). Deletions and microdeletions of 22q11.2 in velo-cardio-facial syndrome. American Journal of Medical Genetics, 44(2), 261–268.
Finucane, B. (2011). 2012 National society of genetic counselors presidential address: Maintaining our professional identity in an ever-expanding genetics universe. Journal of Genetic Counseling, 21(1), 3–6.
Finucane, B., Haas-Givler, B., & Simon, E. W. (2003). Genetics, mental retardation, and the forging of new alliances. American Journal of Medical Genetics, 117C(1), 66–72.
Greenberg, F., Lewis, R. A., Potocki, L., Glaze, D., Parke, J., Killian, J., et al. (1996). Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). American Journal of Medical Genetics, 62(3), 247–254.
Gropman, A. L., Duncan, W. C., & Smith, A. C. M. (2006). Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2). Pediatric Neurology, 34(5), 337–350.
Heath, D., Rapp, R., & Taussig, K. (2004). Genetic citizenship. A Companion to the anthropology of politics. Blackwell.
Jacobs, P. A., Brunton, M., Melville, M. M., Brittain, R. P., & Mcclemont, W. F. (1965). Aggressive behaviour, mental sub-normality and the XYY male. Nature, 208(5017), 1351–1352.
Larson, R. S., & Butler, M. G. (1995). Use of fluorescence in situ hybridization (FISH) in the diagnosis of DiGeorge sequence and related diseases. Diagnostic Molecular Pathology: The American Journal of Surgical Pathology, Part B, 4(4), 274–278.
Ledbetter, D. H. (2008). Cytogenetic technology – genotype and phenotype. New England Journal of Medicine, 359(16), 1728–1730.
Lippmann, A. (1991). The geneticization of health and illness: Implications for social practice. Endocrinologie, 29(1–2), 85–90.
McDonald-McGinn, D. M., & Zackai, E. H. (2008). Genetic counseling for the 22q11.2 deletion. Development Diabilities Research Reviews, 14(1), 69–74.
McDonald-McGinn, D. M., Zackai, E. H., & Low, D. (1997). What’s in a name? The 22q11.2 deletion. American Journal of Medical Genetics, 72(2), 247–249.
McDonald-McGinn, D. M., Kirschner, R., Goldmuntz, E., Sullivan, K., Eicher, P., Gerdes, M., et al. (1999). The Philadelphia story: The 22q11.2 deletion: report on 250 patients. Genetic Counseling (Geneva, Switzerland), 10(1), 11–24.
McDonald-McGinn, D. M., Tonnesen, M. K., Laufer-Cahana, A., Finucane, B., Driscoll, D. A., Emanuel, B. S., et al. (2001). Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: Cast a wide FISHing net! Genetics in Medicine: Official Journal of the American College of Medical Genetics, 3, 23–29.
Miller, D. T., Adam, M. P., Aradhya, S., Biesecker, L. G., Brothman, A. R., Carter, N. P., et al. (2010). Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies, 86(5), 749–764.
Navon, D. (2011). Genomic designation: How genetics can delineate new, phenotypically diffuse medical categories. Social Studies of Science, 41(2), 203–226.
NSGC.org. (2012a). FAQ’s/Definitions. Retrieved February 13, 2012, from http://www.nsgc.org/About/FAQsDefinitions/tabid/97/Default.aspx
NSGC.org. (2012b). FAQs about Genetic Counselors and the NSGC. Retrieved February 13, 2012, from: http://www.nsgc.org/About/FAQsaboutGeneticCounselorsandtheNSGC/tabid/143/Default.aspx
Phelan, M. C. (2011). Interview, March 4th 2011, New York NY.
Phelan, M. C., Rogers, R. C., & Stevenson, R. E. (1988). A de novo terminal deletion of 22q. American Journal Of Human Genetics, 43, A118.
Phelan, M. C., Rogers, R. C., Saul, R. A., Stapleton, G. A., Sweet, K., McDermid, H., et al. (2001). 22q13 deletion syndrome. American Journal of Medical Genetics, 101(2), 91–99.
Potocki, L., Bi, W., Treadwell-Deering, D., Carvalho, C. M. B., Eifert, A., Friedman, E. M., et al. (2007). Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. American Journal of Human Genetics, 80(4), 633–649.
Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Estabrooks Hahn, S., Strecker, M. N., et al. (2006). A new definition of genetic counseling: National society of genetic counselors’ task force report. Journal of Genetic Counseling, 15(2), 77–83.
Shaffer, L. G., Bejjani, B. A., Torchia, B., Kirkpatrick, S., Coppinger, J., & Ballif, B. C. (2007). The identification of microdeletion syndromes and other chromosome abnormalities: Cytogenetic methods of the past, new technologies for the future. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 145C(4), 335–345.
Shaffer, L. G., Coppinger, J., Morton, S. A., Alliman, S., Burleson, J., Traylor, R., et al. (2011). The development of a rapid assay for prenatal testing of common aneuploidies and microdeletion syndromes. Prenatal Diagnosis, 31(8), 778–787.
Smith, A. C., Dykens, E., & Greenberg, F. (1998). Behavioral phenotype of Smith-Magenis syndrome (del 17p11.2. American Journal of Medical Genetics, 81(2), 179–185.
Smith, A. C. M., Gropman, A. L., Bailey-Wilson, J. E., Goker-Alpan, O., Elsea, S. H., Blancato, J., Lupski, J. R., et al. (2002). Hypercholesterolemia in children with Smith-Magenis syndrome: del (17) (p11.2p11.2). Genetics in Medicine: Official Journal of the American College of Medical Genetics, 4(3), 118–125.
Terry, S. F., Terry, P. F., Rauen, K. A., Uitto, J., & Bercovitch, L. G. (2007). Advocacy groups as research organizations: The PXE International example. Nature Reviews Genetics, 8(2), 157–164.
Veltman, J. A., & Brunner, H. G. (2010). Understanding variable expressivity in microdeletion syndromes. Nature Genetics, 42(3), 192–193.
Verkerk, A., Pieretti, M., Sutcliffe, J., Fu, Y., Kuhl, D., Pizzuti, A., et al. (1991). Identification of A Gene (Fmr-1) containing A Cgg Repeat coincident with a breakpoint cluster region exhibiting length variation in fragile-X syndrome. Cell, 65(5), 905–914.
Whitmarsh, I., Davis, A. M., Skinner, D., & Bailey, D. B. (2007). A place for genetic uncertainty: Parents valuing an unknown in the meaning of disease. Social Science & Medicine, 65(6), 1082–1093.
I am grateful for invaluable feedback from Peter Bearman, Claire Edington and Gil Eyal and the generous support of the USA-Israel Binational Science Foundation, grant number 2010175.
About this article
Cite this article
Navon, D. Genetic Counseling, Activism and ‘Genotype-First’ Diagnosis of Developmental Disorders. J Genet Counsel 21, 770–776 (2012). https://doi.org/10.1007/s10897-012-9515-9
- Genetic counseling
- Social studies of science and medicine
- Genotype-first diagnosis
- Ascertainment bias